Keitaro Yokoyama
Jikei University School of Medicine
Internal medicineUrologyEndocrinologySurgeryPathologyRenal functionCardiologyIntensive care medicineHyperphosphatemiaHemodialysisKidney diseaseSecondary hyperparathyroidismPeritoneal dialysisPhosphate binderDialysisKidney transplantationParathyroid hormoneCalciumNephrologyMedicineGastroenterology
215Publications
29H-index
3,066Citations
Publications 216
Newest
#1Kana Asari (Jikei University School of Medicine)H-Index: 1
#2Yukio Maruyama (Jikei University School of Medicine)H-Index: 18
Last. Takashi Yokoo (Jikei University School of Medicine)H-Index: 28
view all 10 authors...
The aim of this study was to compare the changes in peritoneal function and residual renal function in the first year between diabetic and non-diabetic patients receiving peritoneal dialysis (PD). We extracted 73 incident PD patients (male, 73%; age, 59 ± 15 years) from a previous cohort, and investigated the changes in PD-related parameters, including the dialysate to plasma ratio of creatinine (D/P Cr) and Kt/V. D/P Cr increased in non-diabetics, whereas it did not change significantly in diab...
Source
#1Keitaro Yokoyama (Jikei University School of Medicine)H-Index: 29
#2Masafumi Fukagawa (Tokai University)H-Index: 69
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 8 authors...
Etelcalcetide is a second-generation calcimimetic for the management of secondary hyperparathyroidism (SHPT) in patients on dialysis. We performed a post-marketing surveillance (PMS) to obtain information on the safety and efficacy of etelcalcetide in clinical practice in Japan. This PMS enrolled SHPT patients who started initial treatment with etelcalcetide between April 1, 2017 and February 28, 2018 in Japan. Safety [adverse drug reactions (ADRs)] and efficacy [serum intact parathyroid hormone...
1 CitationsSource
#1Masaaki Nakayama (Juntendo University)
#2Chieko Hamada (Juntendo University)H-Index: 19
Last. Toshio Miyata (Tohoku University)H-Index: 98
view all 15 authors...
The ability to visualize intraluminal surface of peritoneal dialysis (PD) catheter and peritoneal cavity could allow elucidation of the cases of outflow problems, and provide information on changes to the peritoneal membrane leading to encapsulating peritoneal sclerosis. A non-invasive examination that allows those monitoring in need is desirable. We have developed a disposable ultra-fine endoscope that can be inserted into the lumen of the existing PD catheter, allowing observation of the lumin...
Source
#1Takashi Shigematsu (Wakayama Medical University)H-Index: 40
#2Masafumi Fukagawa (Tokai University)H-Index: 69
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 7 authors...
AIM: Secondary hyperparathyroidism (SHPT), a complication of haemodialysis, is commonly treated with calcimimetics. The impact of dialysates containing different calcium (Ca) concentrations on clinical efficacy of calcimimetics are unclear. We examined whether dialysate Ca concentrations influence the efficacy and dosing of etelcalcetide with concomitant drugs. METHODS: We performed post hoc analyses of a 52-week, open-label, multicentre study of etelcalcetide in Japanese SHPT patients to determ...
1 CitationsSource
#1Shinji AsadaH-Index: 2
#2Keitaro Yokoyama (Jikei University School of Medicine)H-Index: 29
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 11 authors...
INTRODUCTION: There is limited evidence about the association between calcium and phosphate levels and mortality stratified by intact parathyroid hormone (iPTH) level. METHODS: We investigated whether differences in iPTH level affect the relationship between calcium and phosphate levels and all-cause mortality in hemodialysis patients with secondary hyperparathyroidism (SHPT). Calcium and phosphate levels were categorized as low ( /= 8.5- /= 4.0- /= 9.5 mg/dL, >/= 7.0 mg/dL), respectively. iPTH ...
3 CitationsSource
#1Akio Nakashima (Jikei University School of Medicine)H-Index: 10
#2Kimiyoshi Ichida (Jikei University School of Medicine)H-Index: 34
Last. Takashi Yokoo (Jikei University School of Medicine)H-Index: 28
view all 12 authors...
Dysfunctional variants of ATP-binding cassette transporter subfamily G member 2 (ABCG2), a urate transporter in the kidney and intestine, are the major causes of hyperuricemia and gout. A recent study found that ABCG2 is a major transporter of uremic toxins; however, few studies have investigated the relationship between ABCG2 gene polymorphisms and mortality. This prospective cohort study of 1214 hemodialysis patients investigated the association between serum uric acid levels and ABCG2 genotyp...
2 CitationsSource
#1Risa Ueda (Jikei University School of Medicine)H-Index: 1
#2Masatsugu Nakao (Jikei University School of Medicine)H-Index: 6
Last. Takashi Yokoo (Jikei University School of Medicine)H-Index: 28
view all 12 authors...
Background Several reports on patients with diabetes mellitus (DM) treated by peritoneal dialysis (PD) have shown a higher risk of PD-associated peritonitis compared to non-DM (NDM) patients. The aim of this study was to investigate the incidence of PD-associated peritonitis in DM patients. Methods We divided all patients who received PD at a single center between January 1980 and December 2012 into three groups according to era: Period 1 (n = 43, 1980–1993); Period 2 (n = 123, 1994–2004); and P...
2 CitationsSource
#1Takahito Niikura (Jikei University School of Medicine)H-Index: 4
#2Yukio Maruyama (Jikei University School of Medicine)H-Index: 18
Last. Takashi Yokoo (Jikei University School of Medicine)H-Index: 28
view all 9 authors...
: The serum levels of hepcidin generally increase in patients with chronic kidney disease (CKD) due to inflammation or a decline in the glomerular filtration rate. However, the differences in the ferrokinetics among dialysis modalities are unclear. We investigated the relationship between serum levels of hepcidin and ferritin among non-dialyzed CKD (ND), hemodialysis (HD), and peritoneal dialysis (PD) patients. We recruited 285 CKD patients (117 ND, 80 HD, and 88 PD patients) and measured the se...
2 CitationsSource
#1Keitaro Yokoyama (Jikei University School of Medicine)H-Index: 29
#2Masafumi Fukagawa (Tokai University)H-Index: 69
Last. Hideki HirakataH-Index: 57
view all 8 authors...
Ferric citrate hydrate (FC) is an iron-based phosphate binder approved for hyperphosphataemia in patients with chronic kidney disease. We conducted a randomised controlled trial to evaluate the effects of FC on anaemia management in haemodialysis patients with hyperphosphataemia. We 1:1 randomised 93 patients who were undergoing haemodialysis and being treated with non-iron-based phosphate binders and erythropoiesis-stimulating agents (ESA) to receive 24 weeks of FC or to continue their non-iron...
8 CitationsSource
#1Keitaro Yokoyama (Jikei University School of Medicine)H-Index: 29
#2Ryutaro Shimazaki (Kyowa Hakko Kirin Co., Ltd.)H-Index: 9
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 4 authors...
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic consequences, termed CKD-mineral and bone disorder. Currently, cinacalcet is indicated for the treatment of SHPT; however, cinacalcet is associated with upper gastrointestinal adverse events. Evocalcet has been developed to address these issues, but the long-term safety and efficacy of evocalcet need to be evaluated. To more accurately refl...
8 CitationsSource